The Lancet. Respiratory Medicine Heaney, L G, Busby, J, Hanratty, C E, Djukanovic, R, Woodcock, A, Walker, S M, Hardman, T C, Arron, J R, Choy, D F, Bradding, P, Brightling, C E, Chaudhuri, R, Cowan, D C, Mansur, A H, Fowler, S J, Niven, R M, Howarth, P H, Lordan, J L, Menzies-Gow, A, Harrison, T W, Robinson, D S, Holweg, C T J, Matthews, J G & Pavord, I D 2020, ' Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial ', The Lancet Respiratory Medicine, vol. 9, no. 1, pp. 57-68 . https://doi.org/10.1016/S2213-2600(20)30397-0 Investigators for the MRC Refractory Asthma Stratification Programme 2020, ' Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma : a multicentre, single-blind, parallel group, randomised controlled trial ', The Lancet. Respiratory medicine, vol. 9, no. 1, pp. 57-68 . https://doi.org/10.1016/S2213-2600(20)30397-0